Top Medical News Today
Evan Y. Yu, MD, discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.
The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.
A new drug application (NDA) for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer has been granted a priority review by the FDA.
Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses patterns of response and resistance among hematologic malignancies.
Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).
View More >
Adam M. Brufsky, MD, PhD, discusses considerations for using the bone-targeted agents denosumab and zoledronic acid in patients with breast cancer.
Avelumab Approved by FDA for Merkel Cell Carcinoma
The PD-L1-inhibitor avelumab (Bavencio) has been granted an accelerated approval by the FDA for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.
Enasidenib Granted FDA's Priority Review for IDH2-Mutant AML
A new drug application for enasidenib has been granted a priority review by the FDA as a treatment for patients with relapsed or refractory IDH2-mutated AML.
Alectinib Approved by EC for ALK+ NSCLC
Alectinib has been approved by the European Commission as a treatment for patients with metastatic ALK-positive non-small cell lung cancer following progression on crizotinib.
Avelumab Granted Priority Review by FDA for Metastatic Urothelial Carcinoma
A biologics license application (BLA) for avelumab has been granted a priority review by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed after platinum-based therapy.